PubRank

John N Weinstein

Author PubWeight™ 250.02‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 GoMiner: a resource for biological interpretation of genomic and proteomic data. Genome Biol 2003 22.63
2 Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013 19.87
3 High-Throughput GoMiner, an 'industrial-strength' integrative gene ontology tool for interpretation of multiple-microarray experiments, with application to studies of Common Variable Immune Deficiency (CVID). BMC Bioinformatics 2005 14.02
4 The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 2013 11.29
5 Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011 11.12
6 MatchMiner: a tool for batch navigation among gene and gene product identifiers. Genome Biol 2003 8.66
7 Nova regulates brain-specific splicing to shape the synapse. Nat Genet 2005 6.58
8 Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005 6.46
9 Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med 2015 5.71
10 Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 2006 4.09
11 Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther 2007 3.84
12 A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A 2007 3.78
13 Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 2004 3.72
14 Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A 2003 3.66
15 Mistaken identifiers: gene name errors can be introduced inadvertently when using Excel in bioinformatics. BMC Bioinformatics 2004 3.65
16 Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest 2012 3.64
17 Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping. Cancer Res 2003 3.52
18 An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 2012 3.48
19 Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res 2003 3.42
20 MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther 2008 3.06
21 Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med 2015 3.00
22 AffyProbeMiner: a web resource for computing or retrieving accurately redefined Affymetrix probe sets. Bioinformatics 2007 2.93
23 Molecular interaction maps of bioregulatory networks: a general rubric for systems biology. Mol Biol Cell 2005 2.82
24 Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2012 2.68
25 Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther 2006 2.55
26 DNA fingerprinting of the NCI-60 cell line panel. Mol Cancer Ther 2009 2.53
27 MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther 2007 2.53
28 Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells. Genome Biol 2003 2.52
29 Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov 2013 2.49
30 A stromal gene signature associated with inflammatory breast cancer. Int J Cancer 2008 2.18
31 Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res 2004 2.10
32 Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen. Cancer Res 2008 2.01
33 mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities. Mol Cancer Ther 2010 2.00
34 Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database. Mol Cancer Ther 2009 1.83
35 VirusSeq: software to identify viruses and their integration sites using next-generation sequencing of human cancer tissue. Bioinformatics 2012 1.71
36 Drug discovery: Cell lines battle cancer. Nature 2012 1.70
37 Landscape of DNA virus associations across human malignant cancers: analysis of 3,775 cases using RNA-Seq. J Virol 2013 1.68
38 Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res 2006 1.64
39 TCPA: a resource for cancer functional proteomics data. Nat Methods 2013 1.64
40 Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther 2010 1.62
41 UPLC-ESI-TOFMS-based metabolomics and gene expression dynamics inspector self-organizing metabolomic maps as tools for understanding the cellular response to ionizing radiation. Anal Chem 2008 1.61
42 CellMiner: a relational database and query tool for the NCI-60 cancer cell lines. BMC Genomics 2009 1.58
43 A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. Genes Dev 2013 1.55
44 Quality assessment of microarrays: visualization of spatial artifacts and quantitation of regional biases. BMC Bioinformatics 2005 1.52
45 Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses. Cancer Res 2007 1.51
46 Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res 2003 1.51
47 VennMaster: area-proportional Euler diagrams for functional GO analysis of microarrays. BMC Bioinformatics 2008 1.49
48 The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress. Cancer Res 2005 1.42
49 Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells. Mol Cancer Ther 2007 1.42
50 Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther 2006 1.41
51 The EDGE hypothesis: epigenetically directed genetic errors in repeat-containing proteins (RCPs) involved in evolution, neuroendocrine signaling, and cancer. Front Neuroendocrinol 2008 1.37
52 SpliceSeq: a resource for analysis and visualization of RNA-Seq data on alternative splicing and its functional impacts. Bioinformatics 2012 1.36
53 Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects. Cancer Res 2002 1.34
54 PurityEst: estimating purity of human tumor samples using next-generation sequencing data. Bioinformatics 2012 1.33
55 Sequencing and analysis of 10,967 full-length cDNA clones from Xenopus laevis and Xenopus tropicalis reveals post-tetraploidization transcriptome remodeling. Genome Res 2006 1.31
56 BreakFusion: targeted assembly-based identification of gene fusions in whole transcriptome paired-end sequencing data. Bioinformatics 2012 1.31
57 SpliceCenter: a suite of web-based bioinformatic applications for evaluating the impact of alternative splicing on RT-PCR, RNAi, microarray, and peptide-based studies. BMC Bioinformatics 2008 1.29
58 Chk2 molecular interaction map and rationale for Chk2 inhibitors. Clin Cancer Res 2006 1.28
59 Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines. Mol Cancer Ther 2008 1.28
60 Properties of switch-like bioregulatory networks studied by simulation of the hypoxia response control system. Mol Biol Cell 2004 1.27
61 Molecular interaction maps--a diagrammatic graphical language for bioregulatory networks. Sci STKE 2004 1.27
62 Cancers as wounds that do not heal: differences and similarities between renal regeneration/repair and renal cell carcinoma. Cancer Res 2006 1.26
63 Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health. J Immunother 2005 1.25
64 Exposing the cancer genome atlas as a SPARQL endpoint. J Biomed Inform 2010 1.25
65 SpliceMiner: a high-throughput database implementation of the NCBI Evidence Viewer for microarray splice variant analysis. BMC Bioinformatics 2007 1.25
66 Exon array analyses across the NCI-60 reveal potential regulation of TOP1 by transcription pausing at guanosine quartets in the first intron. Cancer Res 2010 1.24
67 Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers. Mol Cancer Ther 2008 1.22
68 Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther 2008 1.19
69 Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance. Mol Pharmacol 2004 1.18
70 Depicting combinatorial complexity with the molecular interaction map notation. Mol Syst Biol 2006 1.17
71 Human apurinic/apyrimidinic endonuclease (Ape1) and its N-terminal truncated form (AN34) are involved in DNA fragmentation during apoptosis. J Biol Chem 2003 1.08
72 RedundancyMiner: De-replication of redundant GO categories in microarray and proteomics analysis. BMC Bioinformatics 2011 1.08
73 Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study. Cancer Res 2003 1.07
74 Metabolomics reveals attenuation of the SLC6A20 kidney transporter in nonhuman primate and mouse models of type 2 diabetes mellitus. J Biol Chem 2011 1.06
75 Genome-wide analysis of novel splice variants induced by topoisomerase I poisoning shows preferential occurrence in genes encoding splicing factors. Cancer Res 2010 1.05
76 AbMiner: a bioinformatic resource on available monoclonal antibodies and corresponding gene identifiers for genomic, proteomic, and immunologic studies. BMC Bioinformatics 2006 1.04
77 Chromatin challenges during DNA replication: a systems representation. Mol Biol Cell 2007 1.04
78 Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. Biochem Pharmacol 2010 1.00
79 Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas. Clin Cancer Res 2013 0.98
80 Multiplexing siRNAs to compress RNAi-based screen size in human cells. Nucleic Acids Res 2007 0.98
81 Multifactorial regulation of E-cadherin expression: an integrative study. Mol Cancer Ther 2010 0.97
82 Chromosomal instability is associated with higher expression of genes implicated in epithelial-mesenchymal transition, cancer invasiveness, and metastasis and with lower expression of genes involved in cell cycle checkpoints, DNA repair, and chromatin maintenance. Neoplasia 2008 0.94
83 Functional categories associated with clusters of genes that are co-expressed across the NCI-60 cancer cell lines. PLoS One 2012 0.94
84 Karyotypic "state" as a potential determinant for anticancer drug discovery. Proc Natl Acad Sci U S A 2005 0.93
85 Development of gene ontology tool for biological interpretation of genomic and proteomic data. AMIA Annu Symp Proc 2003 0.92
86 Connecting genes, drugs and diseases. Nat Biotechnol 2006 0.91
87 Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers. Cancer Immunol Res 2013 0.90
88 Concordance of gene expression and functional correlation patterns across the NCI-60 cell lines and the Cancer Genome Atlas glioblastoma samples. PLoS One 2012 0.89
89 The LeFE algorithm: embracing the complexity of gene expression in the interpretation of microarray data. Genome Biol 2007 0.89
90 Comparison of methods for sequential screening of large compound sets. Comb Chem High Throughput Screen 2006 0.88
91 Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition. BMC Genomics 2014 0.85
92 In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation. Mol Cancer Ther 2008 0.85
93 An artifact in LC-MS/MS measurement of glutamine and glutamic acid: in-source cyclization to pyroglutamic acid. Anal Chem 2014 0.85
94 Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007. Gynecol Oncol 2007 0.84
95 Identification of common prognostic gene expression signatures with biological meanings from microarray gene expression datasets. PLoS One 2012 0.84
96 Network architecture of signaling from uncoupled helicase-polymerase to cell cycle checkpoints and trans-lesion DNA synthesis. Cell Cycle 2009 0.82
97 Asparagine synthetase: a new potential biomarker in ovarian cancer. Drug News Perspect 2009 0.82
98 Corrigendum: A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun 2015 0.76
99 Ontogenomic study of the relationship between number of gene splice variants and GO categorization. Bioinformatics 2010 0.75
100 Is the gene expression pattern of lung cancer detected by screening with spiral computed tomography different from that of symptom-detected lung cancer? Clin Cancer Res 2004 0.75